XBiotech Inc. (XBIT)
| Market Cap | 88.41M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.41M |
| Shares Out | 30.49M |
| EPS (ttm) | -1.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,270 |
| Open | 2.860 |
| Previous Close | 2.830 |
| Day's Range | 2.860 - 2.900 |
| 52-Week Range | 2.500 - 8.320 |
| Beta | 0.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2025 |
About XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 an... [Read more]
Financial Performance
Financial StatementsNews
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc...
The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into XBiotech Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech ...
XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:...
Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:...
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into XBiotech Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against XBiotech Inc. (XBIT) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:...
XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities a...
Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities a...
Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities a...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against XBiotech Inc. (XBIT) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:...
Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:...
XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , Jan. 17, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBio...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:...
The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into XBiotech Inc For Securities Fraud
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for vi...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities a...
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities a...
The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Inquiry Into XBiotech Inc.
LOS ANGELES, CA / ACCESSWIRE / January 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ...
XBiotech Pauses Rheumatology program
Findings from recently completed Rheumatoid Arthritis Study raise questions Findings from recently completed Rheumatoid Arthritis Study raise questions
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
Tuesday, XBiotech Inc XBIT announced data from its Phase 1/Phase 2, 1-BETTER Study for advanced pancreatic cancer.
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy Findings Show Trends for Reduced Toxicities and Bett...
XBiotech: Several Shots On Goal In Big Target Market Indications
XBiotech Inc.'s Hutrukin is being advanced in a phase 1 study to treat reperfusion injury in patients with ischemic stroke. Other studies being deployed are Natrunix for the treatment of patients with...
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and developmen...